Results 251 to 260 of about 1,982,916 (349)

Multimodal Imaging of Ductal Carcinoma In Situ: A Single-Center Study of 75 Cases. [PDF]

open access: yesMed Sci (Basel)
Urraro F   +7 more
europepmc   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang   +5 more
wiley   +1 more source

Nanoluciferase-CD63 labeling reveals extracellular vesicle kinetics in a mouse intraductal model of ductal carcinoma in situ. [PDF]

open access: yesBreast Cancer Res
Hladik C   +7 more
europepmc   +1 more source

Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives

open access: yesPrecision Medical Sciences, EarlyView.
The smart nano platform in breast cancer treatment is designed with advanced nanocarriers, including liposomes, hydrogels, porous nanoparticles, and aptamer‐based systems. These systems are capable of targeted drug release and response to environmental stimuli.
Tina Rahimi, Moluk Aivazi
wiley   +1 more source

Ultrasonographic Features of Spiradenomas and Cylindromas as Diagnostic Clues in the Pre‐Therapeutic Setting

open access: yes
JEADV Clinical Practice, EarlyView.
Diana Crisan   +5 more
wiley   +1 more source

RNA‐binding protein RBMS1: A new target for cancer diagnosis and treatment

open access: yesPrecision Medical Sciences, EarlyView.
This schematic illustrates the diverse regulatory roles of RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) across multiple human cancers. In breast cancer, RBMS1 stabilizes B4GALT1 mRNA to promote PD‐L1 glycosylation, modulating tumor immune escape and immunotherapy efficacy.
Xingda Run   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy